Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
  • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
  • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/04—Ortho-condensed systems

Definitions

• This invention relates to new compounds, in particular azetidine derivatives, to processes for preparing such compounds, to their use as inhibitors of acetyl-CoA carboxylases, to methods for their therapeutic use, in particular in diseases and conditions mediated by the inhibition of acetyl-CoA carboxylase(s), a nd to pharmaceutical compositions comprising them.
• Background of the invention relates to new compounds, in particular azetidine derivatives, to processes for preparing such compounds, to their use as inhibitors of acetyl-CoA carboxylases, to methods for their therapeutic use, in particular in diseases and conditions mediated by the inhibition of acetyl-CoA carboxylase(s), a nd to pharmaceutical compositions comprising them.
• Obesity is major public health issues not only for the EU, USA, Japan but also for the world in general. It is associated with a number of serious diseases including diabetes, dyslipidemia, hypertension, cardiovascular and cerebrovascular diseases. Although the underlying mechanisms are not yet fully understood, the impairement of insulin action in target tissues by accumulation of excess lipids is generally regarded as a key mechanism linking obesity to secondary pathologies (G. Wolf, Nutrition Reviews Vol. 66(10):597-600; DB Savage, KF Petersen, Gl Shulman, Physiol Rev. 2007;87:507-520). Therefore, understanding of cellular lipid metabolism in insulin target tissues is crucial in order to elucidate the development of diseases associated with obesity.
• a central event in lipid metabolism is the generation of malonyl-CoA via carboxylation of acetyl-CoA by the two mammalian ACC isoforms ACC1 (ACC-alpha, also termed ACCA) and ACC2 (ACC-beta, also designated ACCB) (Saggerson D. Annu Rev Nutr. 2008;28:253-72).
• the malonyl-CoA generated is used for de novo fatty acid synthesis and acts as inhibitor of CPT-1 , thereby regulating mitochondrial fatty acid oxidation.
• malonyl-CoA is also described to act centrally to control food intake, and may play an important role in controlling insulin secretion from the pancreas (GD Lopaschuk, JR Ussher, JS Jaswal. Pharmacol Rev. 2010;62(2):237- 64; D Saggerson Annu Rev Nutr. 2008;28:253-72), further coordinating the regulation of intermediary metabolism.
• ACC1 and ACC2 have been shown to be major regulators of fatty acid metabolism and are presently considered as an attractive target to regulate the human diseases of obesity, diabetes and cardiovascular complications (SJ Wakil and LA Abu-Elheiga, J . Lipid Res. 2009. 50: S1 38-S143; L. Tong , HJ Harwood Jr. Journal of Cellular Biochemistry 99:1476-1488, 2006).
• inhibition of ACC offers the ability to inhibit de novo fatty acid production in lipogenic tissues (liver and adipose) while at the same time stimulating fatty acid oxidation in oxidative tissues (liver, heart, and skeletal muscle) and therefore offers an attractive modality for favorably affecting, in a concerted manner, a multitude of cardiovascular risk factors associated with obesity, diabetes, insulin resistance, and the metabolic syndrome (L. Tong, HJ Harwood Jr. Journal of Cellular Biochemistry 99:1476-1488, 2006; Corbett JW, Harwood JH Jr., Recent Pat Cardiovasc Drug Discov. 2007 Nov;2(3):162-80).
• ACC inhibitors also have the potential to intervene in the progression of diseases that result from the rapid growth of malignant cells or invading organisms that are dependent on endogenous lipid synthesis to sustain their rapid proliferation.
• the potential of ACC inhibitors as antifungal agents and as antibacterial agents is well documented (L. Tong, HJ Harwood Jr. Journal of Cellular Biochemistry 99:1476- 1488, 2006).
• de novo lipogenesis is known to be required for growth of many tumor cells and ACC up-regulation has been recognized in multiple human cancers, promoting lipogenesis to meet the need of cancer cells for rapid growth and proliferation (C Wang, S Rajput, K Watabe, DF Liao, D Cao Front Biosci 2010; 2:515- 26).
• ACC1 associates with and is regulated by the breast cancer susceptibility gene 1 (BRCA1 ).
• BRCA1 breast cancer susceptibility gene 1
• the aim of the present invention is to provide new compounds, in particular new azetidine derivatives, which are active with regard to acetyl-CoA carboxylase(s).
• Another aim of the present invention is to provide new compounds, in particular new azetidine derivatives, which are active with regard to ACC2
• a further aim of the present invention is to provide new compounds, in particular new azetidine derivatives, which have an inhibitory effect on acetyl-CoA carboxylase(s) in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.
• a further aim of the present invention is to provide new compounds, in particular new azetidine derivatives, which have an inhibitory effect on ACC2 in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.
• a further aim of the present invention is to provide effective ACC inhibitors, in particular for the treatment of metabolic disorders, for example of obesity and/or diabetes.
• a further aim of the present invention is to provide methods for treating a disease or condition mediated by the inhibition of acetyl-CoA carboxylase(s) in a patient.
• a further aim of the present invention is to provide a pharmaceutical composition comprising at least one compound according to the invention.
• a further aim of the present invention is to provide a combination of at least one compound according to the invention with one or more additional therapeutic agents.
• a further aim of the present invention is to provide methods for the synthesis of the new compounds, in particular azetidine derivatives.
• a further aim of the present invention is to provide starting and/or intermediate compounds suitable in methods for the synthesis of the new compounds. Further aims of the present invention become apparent to the one skilled in the art by the description hereinbefore and in the following and by the examples.
• R is selected from the group R -G1 consisting of:
• each heterocyclyl may be optionally substituted with aryl or heteroaryl
• each aryl and heteroaryl group may be optionally substituted with one or more substituents R 2 , is selected from the group R c -G1 consisting of:
• each alkyl or cycloalkyl may be optionally substituted with one or more substituents selected from F and OH, and is selected from the group R N1 -G1 consisting of:
• each aryl and heteroaryl group may be optionally substituted with one or more substituents R 2 ,
• R N2 is selected from the group R N2 -G1 consisting of: H and Ci-6-alkyl, and
• Ar 2 is selected from the group Ar 2 -G1 consisting of:
• R 2 is selected from the group R 2 -G1 consisting of:
• each alkyl may be optionally substituted with one or more F-atoms and/ or with a substituent selected from OH, Ci-3-alkyl-O- and CN; and wherein two substituents R 2 attached to an aryl or heteroaryl group may be linked to each other and form a C2-5-alkylene bridging group in which 1 or 2 -
• CH 2 -groups may be replaced by a group independently of each other selected from O, S, NH and N(Ci -4 -alkyl)-, wherein the C2-5-alkylene bridging group is optionally be substituted by 1 or 2 Ci-3-alkyl groups;
• L is selected from the group L-G1 consisting of:
• Ci -4 -alkylene group that is optionally substituted by one or two CH 3 ;
• X is selected from the group X-G1 consisting of: O and S; R is selected from the group R-G1 consisting of: H and Ci-3-alkyl; and
• T is selected from the group T-G1 consisting of:
• each alkyl may optionally be substituted with a heteroaryl group; and wherein each aryl and heteroaryl group may be optionally substituted with one or more substituents R 2 ; including any tautomers and stereoisomers thereof, or a salt thereof or a solvate or hydrate thereof.
• the present invention relates to processes for preparing a compound of general formula (I) and to new intermediate compounds in these processes.
• a further aspect of the invention relates to a salt of the compounds of general formula (I) according to this invention, in particular to a pharmaceutically acceptable salt thereof.
• this invention relates to a pharmaceutical composition, comprising one or more compounds of general formula (I) or one or more pharmaceutically acceptable salts thereof according to the invention, optionally together with one or more inert carriers and/or diluents.
• this invention relates to a method for treating diseases or conditions which are mediated by inhibiting the activity of acetyl-CoA carboxylase(s) in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
• a method for treating a metabolic disease or disorder in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
• a method for treating a cardiovascular disease or disorder in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
• a method for treating a neurodegenerative disease or disorder or for treating a disease or disorder of the central nervous system in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
• this invention relates to a method for treating a disease or condition mediated by the inhibition of acetyl-CoA carboxylase(s) in a patient that includes the step of administering to the patient in need of such treatment a
• this invention relates to a use of a compound of the general formula (I) in combination with one or more additional therapeutic agents for the treatment or prevention of diseases or conditions which are mediated by the inhibition of acetyl-CoA carboxylase(s).
• this invention relates to a pharmaceutical composition which comprises a compound according to general formula (I) or a pharmaceutically acceptable salt thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.
• the groups, residues, and substituents particularly Ar 1 , Ar 2 , X, R, T, R 1 , R 2 , R c , R N1 , R N2 , and L are defined as above and hereinafter. If residues, substituents, or groups occur several times in a compound, as for example R c , R N1 , R N2 or R 2 , they may have the same or different meanings. Some preferred meanings of individual groups and substituents of the compounds according to the invention will be given hereinafter. Any and each of these definitions may be combined with each other.
• the group Ar 1 is preferably selected from the group Ar 1 -G1 as defined hereinbefore and hereinafter.
• the group Ar 1 is selected from the group Ar 1 -G3 consisting of: phenyl, naphthyl, pyridyl, 2H-pyridin-2-onyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, pyrazolyl, thiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, indolyl, benzofuranyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzthiazolyl, benzotriazolyl, oxazolopyrimidinyl, 2,3- dihydrobenzofuranyl, benzo[1 ,3]dioxolyl, 2,3-dihydro-benzo[1 ,4]
• the group Ar 1 is selected from the group Ar 1 -G4 consisting of: phenyl, pyridinyl, pyrimidinyl, benzoxazolyl, benzoisoxazolyl, benzthiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl and oxazolopyrimidinyl, wherein the above-mentioned phenyl, pyridinyl and pyrimidinyl are each substituted with one to three groups independently selected from R 1 , and/or wherein two adjacent carbon atoms of a phenyl group may be linked to each other via a -O-CH 2 -O-, -O-CF 2 -O-, -O-CH 2 -CH 2 -O-, -O-CH 2 -CH 2 -CH 2 -CH 2 -,-O- CH 2 -CH 2 -CH 2 -C(CH 3 ) 2 -, -O-O-
• R 1 may be any of the subgroups of R 1 as defined below. However, with respect to Ar 1 -G4, R 1 is preferably a group selected from the group R 1 -G4 as defined below. Ar 1 -G5:
• the group Ar 1 is selected from the group Ar 1 -G5 consisting of: phenyl, pyridinyl and pyrimidinyl, wherein the above-mentioned phenyl and pyridinyl groups are each substituted with one to three groups independently selected from R 1 , and wherein the above-mentioned pyrimidinyl groups is substituted with one or two R 1 , and wherein two adjacent carbon atoms of a phenyl group may be linked to each other via a -O-CH 2 -CH 2 -O-, -0-CH 2 -CH2-CH2-C(CH3)2-,-0-CH2-CH2-CH 2 -0- > or -O-CH 2 -C(CH 3 )2-CH 2 -O- bridge.
• R 1 may be any of the subgroups of R 1 as defined below. However, with respect to Ar 1 -G5, R 1 is preferably a group selected from the group R 1 -G5 as defined below.
• group Ar 1 is selected from the group Ar 1 -G6 consisting of: phenyl and pyridinyl, which are each optionally substituted with one to three substituents independently selected from the group consisting of:
• Preferred substituents of the phenyl group are:
• group Ar 1 is selected from the group Ar 1 -G6a consisting of:
• phenyl which is optionally substituted with one to three substituents independently selected from the group consisting of:
• cycloalkyl groups may optionally be substituted with one or two F.
• Preferred substituents of the phenyl group are:
• the group R 1 is preferably selected from the group R 1 -G1 as defined hereinbefore and hereinafter,
• the group R 1 is selected from the group R 1 -G4 consisting of: F, CI, Br, CN, Ci -4 alkyl, -O-Ci -4 alkyl, C 3-7 cydoalkyi, -O-C 3-7 cydoalkyi, -O-(Ci -2 alkyl)- C 3-7 cydoalkyi, -NH-C 3-7 cydoalkyi, -NH(Ci -4 alkyl), -CO-O(Ci -4 alkyl), phenyl, -O- phenyl, pyrimidinyl and pyridinyl, wherein the alkyl and cydoalkyi groups may optionally be substituted with one to three F and/or one CN, and wherein the phenyl and pyridinyl groups may optionally be substituted with one F or OCH 3 .
• R 1 -G5 consisting of: F, CI,
• the group R 1 is selected from the group R 1 -G5 consisting of: F, CI, CN, CF 3 , Ci -4 alkyl, -O-Ci -4 alkyl, cyclopropyl, -O-C 3-5 cydoalkyi, -O-CH 2 - cyclopropyl, and
• the group R 1 is selected from the group R 1 -G5a consisting of: F, CI, Br, CN, CF 3 , phenyl, -CO-O-CH 2 CH 3 , -O-phenyl.-O-pyrimidinyl, Ci -3 alkyl, -O- C1-4 alkyl, -O-CH 2 -cyclopropyl and R 1 -G5b:
• the group R 1 is selected from the group R 1 -G5b consisting of: CI, Br, CF 3 , Ci -4 alkyl, -O-Ci -4 alkyl, -CO-O-CH 2 CH 3 , cyclopropyl, phenyl, pyridinyl, - O-CH 2 - cyclopropyl, and
• phenyl and pyridinyl may be substitued by F or -O-CH 3 .
• the group R 1 is selected from the group R 1 -G5c consisting of: -NH-cyclobutyl, -O-cyclobutyl and -NH(CH 2 CH 3 ).
• the group R 1 is selected from the group R 1 -G5d consisting of: CF 3 , -O-(Ci -2 -alkyl), -O-(C 3-4 -cycloalkyl), -O-CH 2 -cyclopropyl and
• the group R c is preferably selected from the group R c -G1 as defined hereinbefore and hereinafter.
• R c is selected from the group R c -G3 consisting of: F, CI, CN, OH and Ci -3 -alkyl-O-.
• R c -G4 is selected from the group R c -G3 consisting of: F, CI, CN, OH and Ci -3 -alkyl-O-.
• the group R c is selected from the group R c -G4 consisting of: F, CN, OH and -O-CH 3 .
• the group R N1 is preferably selected from the group R N1 -G1 as defined hereinbefore and hereinafter.
• R N1 attached to the N-atom of an amino-group it is to be understood that the double or triple bond is preferably not conjugated with the N-atom.
• the group R N1 is selected from the group R N1 -G2 consisting of: H, Ci -4 -alkyl, C 3- 6-cycloalkyl, C 3- 6-cycloalkyl-CH 2 -, heterocydyl, heterocyclyl-CH 2 -, phenyl, phenyl-CH 2 -, pyridyl, pyridyl-CH 2 -, pyrazolyl-CH 2 - and oxazolyl-Ci -3 -alkyl; wherein heterocydyl is defined as hereinbefore and hereinafter, or each heterocydyl is preferably selected from tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl and piperidinyl; and wherein each cycloalkyl and heterocydyl may be optionally substituted with one or two Ci-4-alkyl; and wherein each alkyl, cydoalkyi and
• group R N1 is selected from the group R N1 -G3 consisting of H, Ci -4 -alkyl, C3-6-cycloalkyl-Ci-3-alkyl- and C3-6-cycloalkyl.
• R N2 is preferably selected from the group R N2 -G1 as defined hereinbefore and hereinafter.
• R N2 -G2 :
• the group R N2 is selected from the group R N2 -G2 consisting of H and Ci -4 -alkyl.
• the group R N2 is selected from the group R N2 -G3 consisting of H and CH 3 .
• the group Ar 2 is preferably selected from the group Ar 2 -G1 as defined hereinbefore and hereinafter.
• Ar 2 ⁇ In another embodiment the group Ar 2 is selected from the group Ar 2 -G2 consisting of: phenylene, pyridylene, pyrimidinylene, pyridazinylene, pyrazinylene, furanylene, thienylene, pyrrolylene, imidazolylene, triazolylene, oxazolylene, isoxazolylene, pyrazolylen e and thiazolylene, wherein all of the before mentioned groups may be optionally substituted with one or more substituents R 2 .
• group Ar 2 is selected from the group Ar 2 -G2 consisting of: phenylene, pyridylene, pyrimidinylene, pyridazinylene, pyrazinylene, furanylene, thienylene, pyrrolylene, imidazolylene, triazolylene, oxazolylene, isoxazolylene, pyrazolylen e and thiazolylene, where
• the group Ar 2 is selected from the group Ar 2 -G3 consisting of phenylene and pyridylene, wherein all of the before mentioned groups may be optionally substituted with one to three substituents R 2 .
• the group Ar 2 is selected from the group Ar 2 -G3a consisting of phenylene and pyridylene.
• group Ar 2 is selected from the group Ar 2 -G4 consisting of: phenylene, which may be optionally substituted with one or two substituents R 2 .
• Ar 2 -G4a :
• the group Ar 2 is selected from the group Ar 2 -G4a consisting of phenylene.
• group Ar 2 is selected from the group Ar 2 -G5 consisting of:
• R 2 is preferably selected from the group R 2 -G1 as defined hereinbefore and hereinafter.
• R 2 -G4a :
• the group R 2 is selected from the group R 2 -G4a consisting of: F and -OCH 3 .
• R 2 -G4b :
• the group L is preferably selected from the group L-G1 as defined hereinbefore and hereinafter.
• group L is selected from the group L-G2 consisting of:
• Ci-3-alkylene group that is optionally substituted with one or two CH 3 .
• the group L is selected from the group L-G3 consisting of: a linear Ci-2-alkylene group that is optionally substituted with one CH 3 .
• the group L is selected from the group L-G4 consisting of: -CH(CH 3 )- and -CH(CH 3 )-(CH 2 )-.
• the group L is selected from the group L-G5 consisting of: -CH(CH 3 )- and -CH(CH 3 )-(CH 2 )-,
• the group L is selected from the group L-G6 consisting of -CH(CHs)-.
• a preferred example of the group L-G6a is
• group L-G6a Another preferred example of the group L-G6a is wherein the right-hand side of each of the before-mentiones moieties is attached to the N atom in formula (I) and the left-hand side of each of the before-mentiones moieties is attached to the Ar 2 group.
• the group L is selected from the group L-G7 consisting of: -CH(CH 3 )-(CH 2 )-,
• L-G7a In another embodiment the group L is selected from the group L-G7a consisting of: CH Q
• the group L is selected from the group L-G7b consisting of: wherein the -CH(CH 3 )- moiety of the above group is attached to the N atom in formula (I) and the -CH 2 - * moeity of the above group is attached to the Ar 2 group.
• the group X is preferably selected from the group X-G1 as defined hereinbefore and hereinafter.
• group X is selected from the group X-G2 consisting of O.
• X-G3 is selected from the group X-G2 consisting of O.
• group X is selected from the group X-G3 consisting of S. R:
• the group R is preferably selected from the group R N -G1 as defined hereinbefore and hereinafter.
• R-G2 In another embodiment the group R is selected from the group R N -G2 consisting of H and methyl .
• the group R is selected from the group R N -G3 consisting of H.
• the group T is preferably selected from the group T-G1 as defined hereinbefore and hereinafter.
• heterocyclyl is azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, oxetanyl,
• each heteroaryl is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, isothiazolyl and thiazolyl; and wherein each aryl and heteroaryl group may be optionally substituted with one or more substituents R 2 .
• heterocyclyl is selected from the group consisting of wherein heteroaryl is selected from the group consisting of pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl; and wherein each phenyl and heteroaryl group may be optionally substituted with one or more substituents R 2 .
• the group T is selected from the group T-G5a consisting of: CH 3 ,cyclopropyl and -N(CH 3 ) 2 , wherein the CH 3 group may optionally be substituted with one F, CN, CH 3 , CF 3 , cyclopropyl, -N(CH 3 )2, pyridinyl, OH, or -OCH 3 .
• T-G5b the group T-G5a consisting of: CH 3 ,cyclopropyl and -N(CH 3 ) 2 , wherein the CH 3 group may optionally be substituted with one F, CN, CH 3 , CF 3 , cyclopropyl, -N(CH 3 )2, pyridinyl, OH, or -OCH 3 .
• T-G5b consisting of: CH 3 ,cyclopropyl and -N(CH 3 ) 2 , wherein the CH 3 group may optionally be substituted with one F, CN, CH 3
• the group T is selected from the group T-G5a consisting of: CH 3 and -N(CH 3 ) 2 , wherein the CH 3 group may optionally be substituted with one F, CN, CH 3 , CF 3 , cyclopropyl, -N(CH 3 )2, pyridinyl, OH, or -OCH 3 .
• T-G6 the group T-G6a consisting of: CH 3 and -N(CH 3 ) 2 , wherein the CH 3 group may optionally be substituted with one F, CN, CH 3 , CF 3 , cyclopropyl, -N(CH 3 )2, pyridinyl, OH, or -OCH 3 .
• the group T is selected from the group T-G6 consisting of: CH 3 optionally substituted with one F, CN, CH 3 , CF 3 , cyclopropyl, OH or -OCH 3 .
• the group T is selected from the group T-G6a consisting of: CH 3 .
• the group R T1 is preferably selected from the group R T1 -G1 consisting of H, Ci-6- alkyl, C 3- 6-cycloalkyl, C 3- 6-cycloalkyl-Ci -3 -alkyl, phenyl and pyridyl,
• each cycloalkyi may be optionally substituted with one or more Ci -4 -alkyl
• each alkyl and cycloalkyi may be optionally substituted with one or more substituents selected from F, and
• group R T1 is selected from the group R T1 -G2 consisting of:
• R T1 -G3 H, Ci -4 -alkyl, phenyl and pyridinyl.
• the group R T1 is selected from the group R T1 -G3 consisting of H, methyl and ethyl .
• the group R T2 is preferably selected from the group R T2 -G1 consisting of H and Ci -4 - alkyl .
• the group R T2 is selected from the group R T2 -G2 consisting of H and methyl .
• E-Vd (1.8b) - R 1 -G5d 1 - T-G5 including any tautomers and stereoisomers, solvates, hydrates and salts thereof, in particular the pharmaceutically acceptable salts thereof.
• Preferred are those compounds of formula (I), wherein Ar 1 is selected from the group consisting of phenyl, pyridinyl and pyrimidinyl, wherein the above-mentioned phenyl and pyridinyl groups are each substituted with one to three groups independently selected from R 1 , and wherein the above-mentioned pyrimidinyl groups is substituted with one or two R 1 , and wherein two adjacent carbon atoms of a phenyl group may be linked to each other via a -O-CH 2 -CH 2 -O-, -0-CH 2 -CH2-CH2-C(CH3)2-,-0-CH2-CH2-CH 2 -0- > or -O-CH 2 -C(CH 3 )2-CH 2
• R 1 is selected from the group consisting of F, CI, Br, CN, CF 3 , Ci -4 alkyl, -O-Ci -4 alkyl, cyclopropyl, -O-C 3-5 cycloalkyl, -O-CH 2 - cyclopropyl, and
• Ar 2 is phenylene
• L is a linear Ci-2-alkylene group that is optionally substituted with one CH 3;
• X is O
• R is H
• R T2 is H or CH 3 ; and wherein each alkyl, cycloalkyl and heterocyclyl may be optionally substituted with one F, CN, CH 3 , CF 3 , cyclopropyl, -N(CH 3 ) 2 , pyridinyl, OH or -OCH 3 ; and wherein heteroc clyl is selected from the group consisting of: wherein heteroaryl is selected from the group consisting of pyridyl, pyrimidinyl, pyridazinyl, furanyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl; and wherein each phenyl and heteroaryl group may be optionally substituted with one or two substituents independently selected from CH 3 , -NH-CO- CH 3 , -NH-CO-CH 2 -OH; including any tautomers and stereoisomers thereof,
• the compounds according to the invention may be obtained using methods of synthesis which are known to the one skilled in the art and described in the literature of organic synthesis. Preferably the compounds are obtained analogously to the methods of preparation explained more fully hereinafter, in particular as described in the experimental section.
• Connpounds of general formula (I) may be prepared by palladium-mediated Buchwald reactions or copper-mediated Ullmann reactions of aryl halogenides or aryl triflates (II) with azetidines (III) wherein Z is a leaving group which for example denotes CI, Br, I or OTf (triflate).
• Compounds of general formula (I) may be prepared by amide coupling reactions of amines (IV) with carboxylic acids (V-l) mediated by coupling reagents such as eg 2- (1 H-benzotriazol-1 -yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborat (TBTU), N- hydroxybenzotriazole (HOBt), 2-(1 H-7-azabenzotriazol-1 -yl)-1 ,1 ,3,3-tetramethyl- uronium hexafluorophosphate (HATU) or ⁇ , ⁇ -carbonyldiimidazole (CDI).
• coupling reagents such as eg 2- (1 H-benzotriazol-1 -yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborat (TBTU), N- hydroxybenzotriazole (HOBt), 2-(1 H-7-azabenzotri
• compounds of general formula (I) may be prepared by amide coupling reactions of amines (IV) with carboxylic acids chlorides (V-l I) or carboxylic acid anhydrides (V-lll).
• Compounds of general formula (IX) may be prepared by alkylation reactions of aromatic alcohols (X) with electrophiles (XI) wherein Z is a leaving group which for example denotes CI, Br, I, mesylate, tosylate or triflate and R 3 is Ci-6-alkyl, C3-6- alkenyl, C3-6-alkynyl, C3-io-carbocyclyl, C3-io-carbocyclyl-Ci-3-alkyl, R N1 R N2 N-C2-3- alkyl, heterocyclyl, heterocyclyl-Ci-3-alkyl, aryl, aryl-Ci-3-alkyl, heteroaryl or
• Compounds of general formula (XII) may be prepared by palladium-catalyzed Suzuki coupling reactions of aryl/heteroaryl halogenides or aryl/heteroaryl triflates (XIII) with boronic acids (XIV) or trimethylboroxine wherein Z is a leaving group which for example denotes CI, Br, I or triflate and R 5 is C 2 -6-alkenyl, C 2 -6-alkynyl, aryl or heteroaryl, wherein each aryl and heteroaryl group may be optionally substituted with
• Compounds of general formula (XV) may be prepared by urea forming reactions such as reaction of amines (IV) with amines (XVI) after reaction with reagents such as N,N-carbonylditriazole (CDT) or ⁇ , ⁇ -carbonyldiimidazole (CDI).
• reagents such as N,N-carbonylditriazole (CDT) or ⁇ , ⁇ -carbonyldiimidazole (CDI).
• compounds of general formula (XV) may be prepared by urea forming reactions such as reaction of amines (IV) with carbamoyl chlorides (XVII) or isocyanates (XVIII).
• Compounds of general formula (XX), wherein R is Ci-6-alkyl, C3-io-carbocyclyl or C3- io-carbocyclyl-Ci-3-alkyl, may be prepared by urethane forming reactions such as reaction of amines (IV) with alcohols (IXX) after reaction with reagents such as CDT or CDI. Alcohols may be used in their deprotonated form.
• compounds of general formula (XX) may be prepared by urethane forming reactions such as reaction of amines (IV) with chloro formates (XXI).
• Compounds of general formula (I) may be prepared by alkylation reactions of aromatic alcohols (XXIII) with electrophiles (XXII) wherein Z is a leaving group sucha as for example CI, Br, I, mesylate, tosylate or triflate
• compound(s) according to this invention denote the compounds of the formula (I) according to the present invention including their tautomers, stereoisomers and mixtures thereof and the salts thereof, in particular the pharmaceutically acceptable salts thereof, and the solvates and hydrates of such compounds, including the solvates and hydrates of such tautomers, stereoisomers and salts thereof.
• treatment embraces both preventative, i.e. prophylactic, or therapeutic, i.e. curative and/or palliative, treatment.
• treatment and “treating” comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form.
• Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease.
• compositions and methods of the present invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy.
• treatment and “treating” comprise prophylactic treatment, i.e. a treatment of patients at risk to develop a condition mentioned hereinbefore, thus reducing said risk.
• this invention refers to patients requiring treatment, it relates primarily to treatment in mammals, in particular humans.
• terapéuticaally effective amount means an amount of a compound of the present invention that (i) treats or prevents the particular disease or condition, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or condition, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or condition described herein.
• modulated or modulating or “modulate(s)", as used herein, unless otherwise indicated, refers to the inhibition of acetyl-CoA carboxylase(s) (ACC)(s) with one or more compounds of the present invention.
• mediated refers to the (i) treatment, including prevention the particular disease or condition, (ii) attenuation, amelioration, or elimination of one or more symptoms of the particular disease or condition, or (iii) prevention or delay of the onset of one or more symptoms of the particular disease or condition described herein.
• substituted means that any one or more hydrogens on the designated atom, radical or moiety is replaced with a selection from the indicated group, provided that the atom's normal valence is not exceeded, and that the substitution results in an acceptably stable compound.
• Ci-6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
• the last named subgroup is the radical attachment point, for example, the substituent "aryl-Ci-3-alkyl-" means an aryl group which is bound to a Ci-3-alkyl- group, the latter of which is bound to the core or to the group to which the substituent is attached.
• An asterisk is may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
• the numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.
• 3-carboxypropyl-group represents the following substituent: 3
• each X, Y and Z group is optionally substituted with
• each group X, each group Y and each group Z either each as a separate group or each as part of a composed group may be substituted as defined.
• R ex denotes H, Ci-3-alkyl, C3-6- cycloalkyl, C3-6-cycloalkyl-Ci-3-alkyl or Ci-3-alkyl-O-, wherein each alkyl group is optionally substituted with one or more L ex .” or the like means that in each of the beforementioned groups which comprise the term alkyl, i.e. in each of the groups Ci- 3-alkyl, C3-6-cycloalkyl-Ci-3-alkyl and Ci-3-alkyl-O-, the alkyl moiety may be substituted with L ex as defined.
• bicyclic includes spirocyclic.
• a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc ..) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including
• pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
• pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
• pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
• Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention are also part of the invention.
• halogen generally denotes fluorine, chlorine, bromine and iodine.
• n is an integer from 1 to n, either alone or in
• Ci -5 -alkyl embraces the radicals H 3 C-, H 3 C-CH 2 -, H 3 C-CH 2 -CH 2 -, H 3 C-CH(CH 3 )-, H 3 C-CH2-CH 2 -CH 2 -, H 3 C-CH 2 -CH(CH 3 )-, H 3 C-CH(CH 3 )-CH 2 -, H 3 C-C(CH 3 ) 2 -, H 3 C-CH 2 -CH 2 -CH 2 -CH 2 -, H 3 C-CH 2 -CH 2 -CH(CH 3 )-, H 3 C-CH 2 -CH(CH 3 )-, H 3 C-CH 2 -CH(CH 3 )-CH 2 -, H 3 C-CH(CH 3 )-CH 2 -, H 3 C-CH(CH 3 )-CH 2 -, H 3 C-CH(CH 3 )-CH 2 -, H 3 C-CH(CH 3 )-CH 2 -,
• n is an integer 1 to n, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to n carbon atoms.
• Ci -4 -alkylene includes -(CH 2 )-, -(CH 2 -CH 2 )-, -(CH(CH 3 ))-, -(CH 2 -CH 2 -CH 2 )-, -(C(CH 3 ) 2 )-, - (CH(CH 2 CH 3 ))-, -(CH(CH 3 )-CH 2 )-, -(CH 2 -CH(CH 3 ))-, -(CH 2 -CH 2 -CH 2 -CH 2 )-, -(CH 2 - CH 2 -CH(CH 3 ))-, -(CH(CH 3 )-CH 2 -CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2 )-, -(CH 2 -C(CH 3 ) 2 )-, -(C (CH 3 ) 2 -CH 2
• C 2-n -alkenyl is used for a group as defined in the definition for "Ci -n -alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
• C 2-n -alkenylene is used for a group as defined in the definition for "Ci-n-alkylene” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
• C 2-n -alkynyl is used for a group as defined in the definition for "Ci -n -alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond.
• C 2-3 -alkynyl includes -C ⁇ CH, -C ⁇ C-CH 3 , -CH 2 -C ⁇ CH.
• C 2-n -alkynylene is used for a group as defined in the definition for "Ci-n-alkylene” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond.
• C 2-3 - alkynylene includes -C ⁇ C-, -C ⁇ C-CH 2 -, -CH 2 -C ⁇ C-.
• C 3-n -carbocyclyl denotes a monocyclic, bicyclic or tricyclic, saturated or unsaturated hydrocarbon radical with 3 to n C atoms.
• the hydrocarbon radical is preferably nonaromatic.
• the 3 to n C atoms form one or two rings.
• the rings may be attached to each other via a single bond or may be fused or may form a spirocyclic or bridged ring system.
• C 3- io-carbocyclyl includes C 3- io-cylcoalkyl, C 3- io-cycloalkenyl, octahydropentalenyl, octahydroindenyl, decahydronaphthyl, indanyl, tetrahydronaphthyl.
• C3 -n -carbocyclyl denotes C3 -n -cylcoalkyl, in particular C3-7-cycloalkyl.
• C3 -n -cycloalkyl wherein n is an integer 4 to n, either alone or in
• the cyclic group may be mono-, bi-, tri- or spirocyclic, most preferably monocyclic.
• Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1 .]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.
• C3 -n -cycloalkenyl wherein n is an integer 3 to n, either alone or in combination with another radical, denotes a cyclic, unsaturated but nonaromatic, unbranched hydrocarbon radical with 3 to n C atoms, at least two of which are bonded to each other by a double bond.
• C3 -7 -cycloalkenyl includes cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl and cycloheptatrienyl.
• aryl denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated.
• Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl. More preferably the term "aryl” as used herein, either alone or in combination with another radical, denotes phenyl or naphthyl, most preferably phenyl.
• heterorocydyl is intended to include all the possible isomeric forms. Examples of such groups include aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, azepanyl, piperazinyl, morpholinyl, tetrahydrofuranonyl, tetrahydropyranonyl, pyrrolidinonyl, piperidinonyl, piperazinonyl, morpholinonyl.
• heterocydyl includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
• heteroaryl is intended to include all the possible isomeric forms.
• heteroaryl includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
• the activity of the compounds of the invention may be demonstrated using the following ACC2 assay: Spectrophotometric 384 well assay
• Malonyl CoA formation by acetyl CoA carboxylases is stoichometrically linked to the consumption of ATP.
• ACC2 activity is measured in a NADH-linked kinetic method measuring ADP generated during the ACC reaction using a coupled lactate dehydrogenase / pyruvate kinase reaction.
• a human ACC2 construct which lacks the 128 amino acids at the N-terminus for increased solubility (nt 385-6966 in Genbank entry AJ575592) is cloned.
• the protein is then expressed in insect cells using a baculoviral expression system. Protein purification is performed by anion exchange.
• DMSO dimethyl sulfoxide
• Assay reactions are then carried out in 384-well plates, with hACC2 in an appropriate dilution and at final assay concentrations (f.c.) of 100 mM Tris (pH 7.5), 10 mM trisodium citrate, 25 mM KHCO 3 , 10 mM MgCI 2 , 0.5 mg/ml BSA, 3.75 mM reduced L-glutathione, 15 U/ml lactate dehydrogenase, 0.5 mM phosphoenolpyruvate, 15 U/ml pyruvate kinase, compounds at different concentrations at final DMSO concentrations of 1 %.
• the enzymatic reaction is then started by addition of a mixture of NADH, acetyl Coenzyme A (both 200 ⁇ f.c.) and ATP (500 uM f.c).
• the decrease of the optical density (slope S) is then determined at 25°C at a wavelength of 340 nm over 1 5 minutes in a spectrophotometric reader.
• Each assay microtiter plate contains wells with vehicle instead of compound as controls for the non-inhibited enzyme (100% CTL; 'HIGH') and wells without acetyl-
• %CTL (S(compound)-S('LOW'))/(S('HIGH')-
• the compounds of general formula (I) according to the invention for example have IC 5 o values below 15000 nM, particularly below 1000 nM, preferably below 300 nM.
• the compounds of general formula (I) according to the invention and the corresponding salts thereof are theoretically suitable for the treatment, including preventative treatment of all those diseases or conditions which may be affected or which are mediated by the inhibition of acetyl-CoA carboxylase(s), in particular ACC2, activity.
• the present invention relates to a compound of general formula (I) as a medicament.
• the present invention relates to the use of a compound of general formula (I) for the treatment and/or prevention of diseases or conditions which are mediated by the inhibition of acetyl-CoA carboxylase(s), in particular ACC2, in a patient, preferably in a human.
• the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of acetyl-CoA
• carboxylase(s) in a mammal that includes the step of administering to a patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.
• acetyl-CoA carboxylases embrace metabolic and/or cardiovascular and/or neurodegenerative diseases or conditions.
• the compounds of the present invention are particularly suitable for treating diabetes mellitus, in particular Type 2 diabetes, Type 1 diabetes, and diabetes-related diseases, such as ishyperglycemia, metabolic syndrome, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, dyslipidemia, hypertension, hyperinsulinemia, and insulin resistance syndrome, hepatic insulin resistance, including complications such as macro- and microvascular disorders, including thromboses, hypercoagulable and prothrombotic states (arterial and venous), high blood pressure, coronary artery disease and heart failure, increased abdominal girth, hypercoagulability, hyperuricemia, micro- albuminemia.
• diabetes-related diseases such as ishyperglycemia, metabolic syndrome, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, dyslipidemia, hypertension, hyperinsulinemia, and insulin resistance syndrome, hepatic insulin resistance, including complications such as macro- and microvascular disorders, including thromboses, hypercoagulable and prothrombo
• the compounds of the present invention are particularly suitable for treating overweight, obesity, including visceral (abdominal) obesity, nonalcoholic fatty liver disease (NAFLD) and obesity related disorders, such as for example weight gain or weight maintenance
• BMI body mass index
• Overweight is typically defined as a BMI of 25-29.9 kg/m 2
• obesity is typically defined as a BMI of 30 kg/m 2 or greater.
• the compounds of the present invention are particularly suitable for treating, inclduing preventing, or delaying the progression or onset of diabetes or diabetes-related disorders including Type 1 (insulin-dependent diabetes mellitus, also referred to as "IDDM”) and Type 2 (noninsulin-dependent diabetes mellitus, also referred to as “NIDDM”) diabetes, impaired glucose tolerance, insulin resistance, hyperglycemia, pancreatic beta cell degeneration and diabetic complications (such as macro- and microvascular disorders, atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, nephropathy,
• IDDM insulin-dependent diabetes mellitus
• NIDDM noninsulin-dependent diabetes mellitus
• the compounds of the present invention are suitable for treating
• dyslipidemias in general and more specifically elevated lipid concentrations in the blood and in tissues, dysregulation of LDL, HDL and VLDL, in particular high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, low HDL cholesterol concentration, low apoA lipoprotein concentrations, high LDL cholesterol concentrations, high apoB lipoprotein concentrations, including
• Atherosclerosis coronary heart disease, cerebrovascular disorders, diabetes mellitus, metabolic syndrome, obesity, insulin resistance and/or cardiovascular disorders.
• ACC inhibition may lead to a centrally stimulating effect on food intake. Therefore compounds of the present invention may be suitable for treating eating disorders such as anorexia nervosa.
• the compounds of the present invention may provide neuroprotective effects in patients with Parkinson's disease, Alzheimer's disease, hypoxia, ischemia, amyotrophic lateral sclerosis or glioma and may improve cognitive scores in
• inhibitors of acetyl-CoA carboxylases embrace but are not limited to:
• disorders of fatty acid metabolism and glucose utilization disorders disorders in which insulin resistance is involved;
• NASH steatohepatitis
• alcoholic hepatitis acute fatty liver, fatty liver of pregnancy, drug-induced hepatitis, iron storage diseases, hepatic fibrosis, hepatic cirrhosis, hepatoma, viral hepatitis
• C skin disorders and conditions and those associated with polyunsaturated fatty acids, such as
• apoCII or apoE deficiency familial histiocytic reticulosis, lipoprotein lipase deficiency, hyperlipoproteinemias, apolipoprotein deficiency (e.g. apoCII or apoE deficiency);
• E. diseases or conditions related to neoplastic cellular proliferation for example benign or malignant tumors, cancer, neoplasias, metastases, carcinogenesis;
• - atherosclerosis such as, for example (but not restricted thereto), coronary sclerosis including angina pectoris or myocardial infarction, stroke, ischemic, stroke and transient ischemic attack (TIA),
• coronary sclerosis including angina pectoris or myocardial infarction
• stroke ischemic
• stroke transient ischemic attack
• - lipomatous carcinomas such as, for example, liposarcomas
• - solid tumors and neoplasms such as, for example (but not restricted thereto), carcinomas of the gastrointestinal tract, of the liver, of the biliary tract and of the pancreas, endocrine tumors, carcinomas of the lungs, of the kidneys and the urinary tract, of the genital tract, prostate carcinomas, breast cancer (in particular breast cancer with BRCA1 mutations), etc.,
• Alzheimer's disease including Alzheimer's disease, multiple sclerosis, Parkinson's disease, epilepsy,
• erythemato-squamous dermatoses such as, for example, psoriasis
• - dermatitis such as, for example, seborrheic dermatitis or photodermatitis
• keratitis and keratoses such as, for example, seborrheic keratoses, senile keratoses, actinic keratoses, photo-induced keratoses or keratosis follicularis,
• HPV human papilloma viral infections
• viruses such as, for example, venereal papillomata
• viral warts such as, for example, molluscum contagiosum, leukoplakia
• - papular dermatoses such as, for example, lichen planus
• - skin cancer such as, for example, basal-cell carcinomas, melanomas or cutaneous T-cell lymphomas,
• PCOS polycystic ovary syndrome
• rheumatoid arthritis - lupus erythematosus (LE) or inflammatory rheumatic disorders such as, for example rheumatoid arthritis,
• ARDS acute respiratory distress syndrome
• lipid myopathis such as carnitine palmitoyltransferase I or II deficiency
• the dose range of the compounds of general formula (I) applicable per day is usually from 0.001 to 10 mg per kg body weight, for example from 0.01 to 8 mg per kg body weight of the patient.
• Each dosage unit may conveniently contain from 0.1 to 1000 mg, for example 0.5 to 500 mg.
• the actual therapeutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a therapeutically effective amount to be delivered based upon patient's unique condition.
• Suitable preparations for administering the compounds of formula (I) will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injectables, inhalatives and powders etc.
• the content of the pharmaceutically active compound(s) is advantageously in the range from 0.1 to 90 wt.-%, for example from 1 to 70 wt.-% of the composition as a whole.
• Suitable tablets may be obtained, for example, by mixing one or more compounds according to formula (I) with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
• excipients for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
• the tablets may also consist of several layers.
• the compounds of the invention may further be combined with one or more, preferably one additional therapeutic agent.
• the additional therapeutic agent is selected from the group of therapeutic agents useful in the treatment of diseases or conditions associated with metabolic diseases or conditions such as for example diabetes mellitus, obesity, diabetic complications, hypertension, hyperlipidemia.
• a compound of the invention may be combined with one or more additional therapeutic agents selected from the group consisting of anti-obesity agents
• agents which lower blood glucose include appetite suppressants, agents which lower blood glucose, anti-diabetic agents, agents for treating dyslipidemias, such as lipid lowering agents, antihypertensive agents, antiatherosclerotic agents, anti-inflammatory active ingredients, agents for the treatment of malignant tumors, antithrombotic agents, agents for the treatment of heart failure and agents for the treatment of complications caused by diabetes or associated with diabetes.
• Suitable anti-obesity agents include 1 1 beta-hydroxy steroid dehydrogenase-1
• beta-HSD type 1 inhibitors
• SCD-1 stearoyl-CoA desaturase-1
• MCR-4 agonists stearoyl-CoA desaturase-1
• CCK-A cholecystokinin-A
• monoamine reuptake inhibitors sympathomimetic agents
• beta3 adrenergic agonists dopamine agonists
• melanocyte-stimulating hormone analogs melanocyte-stimulating hormone analogs, 5HT2c agonists, melanin concentrating hormone antagonists, leptin (the OB protein), leptin analogs, leptin agonists, galanin antagonists, lipase inhibitors, anorectic agents, neuropeptide-Y antagonists (e.g., NPY Y5 antagonists), ⁇ 3-36 (including analogs thereof), thyromimetic agents, dehydroepiandrosterone or an analog thereof, glucocorticoid agonists or antagonists, orexin antagonists, glucagon-like peptide-1 agonists, ciliary neurotrophic factors, human agouti-related protein (AGRP) inhibitors, ghrelin antagonists, histamine 3 antagonists or inverse agonists, neuromedin U agonists, MTP/ApoB inhibitors (e.g., gut-selective MTP inhibitors), opioid antagonist, or
• Preferred anti-obesity agents for use in the combination aspects of the present invention include gut-selective MTP inhibitors CCKa agonists, 5HT2c agonists, MCR4 agonist, lipase inhibitor, opioid antagonists, oleoyl-estrone, obinepitide, pramlintide (Symlin®), tesofensine (NS2330), leptin, liraglutide, bromocriptine, orlistat, exenatide (Byetta®), AOD-9604 (CAS No. 221231 -10-3) and sibutramine.
• Suitable anti-diabetic agents include a sodium-glucose co-transporter (SGLT) inhibitor, a phosphodiesterase (PDE) 10 inhibitor, a diacylglycerol acyltransferase (DGAT) 1 or 2 inhibitor, a sulfonylurea (e.g., acetohexamide, chlorpropamide, diabinese, glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide, and tolbutamide), a meglitinide, an alpha- amylase inhibitor (e.g., tendamistat, trestatin and AL-3688), an alpha-glucoside hydrolase inhibitor (e.g., acarbose), an alpha-glucosidase inhibitor (e.g., adiposine, camiglibose, e
• DPP-IV dipeptidyl peptidease IV
• antidiabetic agents are metformin, a glucagon-like peptide 1 (GLP-1 ) agonist (e.g., ByettaTM) and DPP-IV inhibitors (e.g. sitagliptin, vildagliptin, alogliptin, linagliptin and saxagliptin).
• GLP-1 glucagon-like peptide 1
• DPP-IV inhibitors e.g. sitagliptin, vildagliptin, alogliptin, linagliptin and saxagliptin.
• compounds of the present invention and/or pharmaceutical compositions comprising a compound of the present invention optionally in combination with one or more additional therapeutic agents are administered in conjunction with exercise and/or a diet.
• this invention relates to the use of a compound according to the invention in combination with one or more additional therapeutic agents described hereinbefore and hereinafter for the treatment or prevention of diseases or conditions which may be affected or which are mediated by the inhibition of acetyl-CoA carboxylase(s), in particular ACC2, in particular diseases or conditions as described hereinbefore and hereinafter.
• the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of acetyl-CoA
• carboxylase(s) in a patient that includes the step of administering to the patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of one or more additional therapeutic agents described in hereinbefore and hereinafter,
• the compound according to the invention and the one or more additional therapeutic agents may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so- called kit-of-parts.
• this invention relates to a pharmaceutical composition which comprises a compound according to the invention and one or more additional therapeutic agents described hereinbefore and hereinafter, optionally together with one or more inert carriers and/or diluents.
• aspects of the invention include the use of a compound according to the invention or a salt thereof as a crop protection agent to combat and/or prevent fungal infestations, or to control other pests such as weeds, insects, or acarids that are harmful to crops.
• Another aspect of the invention relates to the use of a compound according to the invention or a salt thereof for controlling and/or preventing plant pathogenic microorganisms, for example plant pathogenic fungi. Therefore one aspect of the invention is a compound according to the formula (I) or a salt thereof for use as a fungicide, insecticide, acaricide and/or herbicide.
• Another aspect of the invention relates to an agricultural composition comprising a compound of the present invention together with one or more suitable carriers.
• Another aspect of the invention relates to an agricultural composition comprising a compound of the present invention in combination with at least one additional fungicide and/or systennically acquired resistance inducer together with one or more suitable carriers.
• ambient temperature and “room temperature” are used interchangeably and designate a temperature of about 20 °C.
• Chiral H P Chiral — 7 ⁇ .20 go (33.0- mmrol) of. example II are added to - 80 mL ⁇ DCM- ande charg-ed with 18.5 mL (132 mmol) TEA. After cooling down to 0 °C 5.88 g (36.3 mmol) CDI are added, the cooling is removed and stirring is continued for 20 min. 4.46 g (99.0 mmol) dimethyl- amine are added an the mixture is stirred at r.t. over night. 1 N aq. citic acid is added, the phases are separated and the aq. phase is is extracted one more time with DCM. The org. phases are combined, dried with MgSO 4 and the solvent is removed in vacuo. The crude product is purified by column chromatography (silica gel,
• example XII 7.20 g (15.7 mmol) of example XII are added to 50 mL EtOH and charged with 1 .00 g Pd/C (10%).
• the reaction mixture is hydrogenated at r.t. for 24 h at a hydrogen pressure of 3 bar.
• the reaction mixture is filtered and the solvent is removed in vacuo.
• the crude product is triturated with TBME.
• reaction temperature 120 °C.
• reaction temperature 140 °C and the product is purified by column chromatography (silica gel, PE/EtOAc 8/2).
• step a To the diphenol and dibromoethane (8 eq.) in acetone is added CS2CO3 (5 eq.) and the reaction mixture is stirred at 90 °C for 45 h. The reaction mixture is quenched by the addition of water and extracted with EtOAc.
• XVII.6 the phenol is added to THF, deprotonated with NaH at 0 °C and after the addition of dibromoethane the reaction mixture is refluxed for 16 h followed by an aq. work up.
• reaction mixture is stirred at r.t. for 3 h.
• the intermediates from step a are purified by HPLC after the filtration over basic aluminium oxide.
• example III Under inert gas atmosphere 200 mg (0.77 mmol) of example III are added to a 1/1 mixture of dioxane and water. Then 240 mg (4.20 mmol) powdered KOH and

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Diabetes (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Child & Adolescent Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47358497

Family Applications (1)

Country Status (4)

Cited By (4)

Families Citing this family (4)

Citations (7)

Family Cites Families (5)

• 2012
  • 2012-12-14 US US13/714,511 patent/US8530460B2/en active Active
  • 2012-12-18 EP EP12801768.8A patent/EP2794586B1/en not_active Not-in-force
  • 2012-12-18 JP JP2014547934A patent/JP6051457B2/ja not_active Expired - Fee Related
  • 2012-12-18 WO PCT/EP2012/075996 patent/WO2013092616A1/en not_active Ceased

Patent Citations (7)

Non-Patent Citations (18)

Also Published As

Similar Documents

Legal Events